Can NMN Affect Blood Pressure or Heart Health?

Does NMN Raise Blood Pressure? What the Trials Show

Blood pressure is a standard safety endpoint in clinical trials and is monitored at every visit in well-designed supplement trials. This means the NMN human trial database includes regular blood pressure assessments across dozens of visits and hundreds of participants. The consistent finding: no clinically significant change in blood pressure attributable to NMN supplementation.

Multiple completed trials, including the Fukamizu et al. 2022 safety trial at 1250 mg daily, the Kim et al. 2022 trial in older adults, the Igarashi et al. 2022 trial in older men, and the Yi et al. 2023 multicenter dose-dependent trial, all included blood pressure monitoring as part of standard safety assessment. None reported blood pressure elevation as an adverse event related to NMN. In the Fukamizu safety trial, one participant in the NMN group did report an episode of high blood pressure, but the investigators determined this was unrelated to NMN administration, and the participant recovered fully.

The absence of blood pressure effects from NMN is pharmacologically consistent with its mechanism. NMN is a NAD+ precursor. It does not interact with the renin-angiotensin-aldosterone system, does not affect sodium-potassium balance through direct renal mechanisms, does not have vasoconstrictive properties, and does not activate adrenergic receptors. There is no mechanistic pathway through which NMN at supplement doses would be expected to raise blood pressure.

NMN and Vascular Biology: What the Science Shows

While NMN does not raise blood pressure, the more interesting cardiovascular story is what NMN does to ageing blood vessels. NAD+ plays a central role in endothelial cell function, and the age-related decline in NAD+ is now recognised as a significant contributor to vascular ageing.

This study addresses three of the most important cardiovascular ageing mechanisms simultaneously: endothelial dysfunction (the loss of blood vessels' ability to dilate in response to flow), arterial stiffness (a major independent risk factor for cardiovascular events and all-cause mortality), and vascular oxidative stress (a driver of endothelial damage and atherogenesis). NMN's restoration of all three via SIRT1 activation represents a mechanistically coherent anti-ageing vascular effect.

The findings are from animal research and have not been replicated in equivalent human vascular endpoint trials. This is an important caveat. But the mechanistic basis is sound and consistent with what is understood about the role of NAD+ and SIRT1 in endothelial health.

Endothelial Function: The Cardiovascular Significance of NAD+

Endothelial cells line every blood vessel in the body. Their health is foundational to cardiovascular function. Healthy endothelium produces nitric oxide (NO), which signals underlying smooth muscle cells to relax, allowing vessels to dilate in response to increased blood flow demand. With age, endothelial NO production declines, vessels become less responsive, blood pressure tends to rise, and arterial walls stiffen. This process is called endothelial dysfunction and is a precursor to hypertension, atherosclerosis, and cardiac events.

NAD+ is essential for endothelial NO production and endothelial cell energy metabolism. As endothelial NAD+ declines with age, NO signalling weakens, oxidative stress in the vessel wall increases, and inflammatory gene expression rises. The De Picciotto 2016 findings show that NMN-driven NAD+ restoration can reverse these changes in aged animals, restoring NO-dependent vasodilation and reducing arterial oxidative stress to levels seen in young controls.

SIRT1 is the mediating protein in this process. SIRT1 activity in endothelial cells is NAD+-dependent: as NAD+ declines with age, SIRT1 becomes less active, and its protective effects on endothelial function are reduced. By restoring NAD+ via NMN, SIRT1 is reactivated in the vascular endothelium, and its downstream effects on NO production, anti-inflammatory gene expression, and oxidative stress management are restored. This is the same NAD+/SIRT1 axis that underlies many of NMN's other proposed benefits, operating here at the level of the arterial wall.

Arterial Stiffness: An Underappreciated Ageing Risk Factor

Arterial stiffness is measured clinically by pulse wave velocity (PWV), the speed at which pressure waves travel along the arterial wall. Higher PWV means stiffer arteries. Age-related arterial stiffness is an independent predictor of cardiovascular events, stroke risk, and all-cause mortality, separate from blood pressure levels themselves.

The De Picciotto 2016 study found that NMN reduced aortic pulse wave velocity in aged mice from 464 cm/s (aged controls) to 359 cm/s (NMN-treated aged mice), approaching the 337 cm/s seen in young mice. It also reduced elastic modulus (a measure of aortic wall stiffness) and reversed age-associated changes in collagen and elastin content of the aortic wall. Collagen accumulation and elastin loss are the structural basis of arterial stiffening with age; NMN reversed both.

These findings are meaningful because arterial stiffness is one of the cardiovascular consequences of NAD+ decline that most directly affects blood pressure and cardiac workload. When arteries stiffen, the heart must work harder to pump blood, isolated systolic hypertension tends to develop, and the cushioning function of the aorta during the cardiac cycle is compromised. If NMN's effect on arterial stiffness in aged animals translates to humans, it would represent a meaningful cardiovascular protection mechanism beyond simply managing blood pressure symptoms.

Blood Flow and Capillary Density

Beyond large artery function, NMN has also been studied for its effects on the microcirculation: the network of capillaries that delivers oxygen and nutrients to tissues. Capillary density declines with age, contributing to reduced tissue oxygenation, exercise intolerance, and frailty.

Research from Sinclair's laboratory at Harvard Medical School (Das et al., published in Cell, 2018) demonstrated that NMN supplementation in aged mice restored capillary density in skeletal muscle to levels comparable to young mice and significantly improved exercise endurance, both through a SIRT1-dependent mechanism. The study established that declining NAD+ in endothelial cells reduces SIRT1 activity and impairs the formation of new blood vessels in response to exercise stimulation, and that NMN restores this capacity in aged animals.

For human longevity purposes, this capillary restoration finding is relevant to maintaining physical performance, muscle health, and the cardiovascular response to exercise as we age. Clinical trials examining NMN's effects on aerobic capacity (including the Liao et al. 2021 runner study showing improved aerobic performance) may partly reflect this vascular mechanism alongside the mitochondrial benefits.

Human Cardiovascular Safety Profile

Stepping from animal research back to the human evidence: the cardiovascular safety record of NMN in completed human trials is clean. The specific markers assessed include:

Blood pressure: Monitored in all major trials at every assessment point. No clinically significant changes attributable to NMN. One reported episode of high blood pressure in the Fukamizu trial determined to be unrelated to supplementation.

Heart rate: Monitored as part of vital sign assessment in multiple trials. No clinically significant changes.

Lipid profile (cholesterol, triglycerides): Assessed in multiple safety and efficacy trials. No adverse changes. Some trials reported numerically lower triglycerides in the NMN group, which is consistent with NMN's metabolic effects.

ECG: Electrocardiographic assessment was included in some trials. No arrhythmia signals or conduction abnormalities attributable to NMN.

Cardiac-relevant enzymes: Liver and muscle enzymes assessed in safety panels did not show abnormal elevations suggesting cardiac muscle involvement.

NMN and People with Pre-Existing Cardiovascular Conditions

The clean safety record from completed NMN trials applies to the populations studied: primarily healthy adults without significant cardiovascular disease. The specific safety data for people with established hypertension, coronary artery disease, heart failure, atrial fibrillation, or those taking cardiovascular medications is more limited.

A small observational study in hypertensive patients found that NMN supplementation combined with lifestyle modifications was associated with greater blood pressure reductions than lifestyle modifications alone, suggesting NMN may be beneficial rather than harmful in people with hypertension. This is preliminary, single-study evidence and cannot be used to make treatment recommendations.

For people with established cardiovascular conditions, the practical guidance is straightforward: discuss NMN with your cardiologist before starting. This is not because there is a known risk signal in cardiac populations, but because personalised guidance from a physician familiar with your specific condition and medication regimen is appropriate for any new supplement when you have a cardiovascular diagnosis.

Frequently Asked Questions

Can NMN raise blood pressure?

No. Human clinical trials monitoring blood pressure as a safety endpoint have not found NMN to raise blood pressure at doses up to 1250 mg daily. Preclinical data suggests NMN's vascular effects may go in the opposite direction, restoring endothelial function and reducing arterial stiffness in aged animals.

Is NMN good for heart health?

Preclinical evidence shows NMN restores endothelial nitric oxide production, reduces arterial stiffness, lowers vascular oxidative stress, and improves capillary density in aged animals via SIRT1 activation. Human cardiovascular outcomes data from large long-term trials does not yet exist. The available human safety data shows no adverse cardiovascular signals, and the mechanistic evidence from animal research is promising.

Can NMN cause heart palpitations?

Heart palpitations are not a documented adverse event in any completed NMN human clinical trial. Electrocardiographic assessment in some trials found no adverse findings. NMN's mechanism does not include direct cardiac electrophysiological effects. Persistent palpitations should always be evaluated by a physician regardless of supplement use.

Is NMN safe for people with heart conditions?

Completed NMN trials enrolled generally healthy adults, not people with established cardiovascular disease. The clean safety record in healthy adults is reassuring, but specific data for cardiac populations is limited. People with known heart disease, arrhythmias, or on cardiovascular medications should consult their cardiologist before starting NMN.

What does NMN do for blood vessels?

Preclinical research shows NMN restores endothelium-dependent vasodilation, reduces arterial stiffness, decreases arterial wall oxidative stress, and restores vascular SIRT1 activity in aged mice. These effects reflect restoration of age-related vascular dysfunction via NAD+ replenishment. These are animal findings; equivalent human vascular endpoint studies are not yet completed.

Does NMN interact with blood pressure medications?

No significant interactions between NMN and antihypertensive medications have been identified. However, NMN has not been systematically tested in people taking cardiovascular medications. People on antihypertensives or other cardiovascular drugs should inform their prescribing physician before starting NMN as a precaution and to allow appropriate monitoring.

Can NMN lower blood pressure?

There is preliminary evidence from a small observational study suggesting NMN combined with lifestyle modification may reduce blood pressure more than lifestyle modification alone in hypertensive patients. This is insufficient to classify NMN as a blood pressure-lowering intervention. Human trials have not used blood pressure reduction as a primary efficacy endpoint for NMN.